A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).

Trial Details

NCT ID
NCT07310420
Phase
PHASE1
Sponsor
TerSera Therapeutics LLC
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • ZOLADEX
Locations (sample)
  • Hot Springs, Arkansas, United States|34.5037,-93.05518
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Ocoee, Florida, United States|28.56917,-81.54396
  • Savannah, Georgia, United States|32.08354,-81.09983
  • Lisle, Illinois, United States|41.80114,-88.07479

Key Eligibility Criteria

  • Age and gender:
  • Gonadotropin-releasing Hormone (GnRH) treatment-naïve: Female participants aged 18 to 55 years, inclusive.
  • GnRH treatment-exposed \<6 months: Female participants aged 18 to 55 years, inclusive, if GnRH treatment started within \<6 months of signing the i…
  • Advanced or metastatic breast cancer: Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →